Targeted inhibition of the NUP98-NSD1 fusion oncogene in myelodysplastic syndromes and acute myeloid leukaemia models by NSD1 inhibitors (WP2)
Rationale and objectives
We will analyze the efficiency of epigenetic drugs as a mechanism to decrease aberrant histone methylation activity in myelodysplastic syndrome (MDS) and secondary Acute Myeloid Leukaemia (sAML) driven by the fusion protein of NUP98 and the histone methylase NSD1.
Our tasks are:
• To determine the effect of NSD1 inhibitors in murine and human cells with NUP98-NSD1 on the level of cell biology.
• To study the genome-wide patterns of histone modifications before and after the treatment in order to identify target loci.
• To understand the impact of NSD1 inhibition on intercellular heterogeneity by perform scRNA-seq.
Veterinärmedizinische Universität Wien (Austria, 4 months). Depending on the project development: Aelian Bio (Austria, 1 month).
PhD in Cell Biology, Autonomous University of Barcelona (UAB), Spain.